In the Board Room just about 3-4 board members have important seats. The rest are chair weights. One of them is Karin’s chair. I let you figure out who are the other couple of BOD members are. Dinner doesn’t need chair weights in the board room.
But considering current sentiment towards Amarin management
I think sentiment expressed on this board does not necessarily reflects the current sentiment of all shareholders ... at least the votes suggests this. I mean: Meanwhile Sarissa gave a notice in advance about "Abstain" less than the 50% of outstanding voted (188 / 400) and - by thigh margin, but - "For" was more than "Against + Abstain".
Is it the best management ever? Definitely not, but they are OK. Looks like they are doing "everything" for long term success.
US: - restructuring the operation (inc. cut sales force, cur and reallocate marketing expense between "channels") - secure app. 50% of the market (the script# - at least - was stabilized in this segment and a good basis for growth ... this could "force" one or more generic to leave the market on mid- / long-term ... please note: Teva or Apotex did not enter)
EU: - they submitted the application in all key markets ... secured UK (& Sweden) and - at least - Germany and France will come during the next few months - the process takes time ... they are not slow. IF we "accept" that they are slow, it is because they are not give up long-term opportunity (higher price) for "speed" / short-term gain (earlier agreement) - they secured (and more likely will in other countries) a very good price and reimbursement (e.g. highest category in France). IIRC drug prices in the EU are lower (usually) than in the US but Vascepa secured higher price than the V's price before generic - ongoing discussion for non-GIA EU countries / regions
Rest of the world: - submitted application in several market - ongoing discussion for several countries / regions
News 
Market Data 
Discover 
